



# SAFETY DATA SHEET

Revision date 17-Jun-2025

Version 2

Page 1 / 11

## Section 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

### 1.1. Product identifier

**Product Name** Cefazolin for Injection (Hospira, Inc.)  
**Product Code(s)** PZ03062  
**Trade Name:** Not applicable  
**Chemical Family:** Cephalosporin antibiotic

### 1.2. Relevant identified uses of the substance or mixture and uses advised against

**Recommended Use** Pharmaceutical product used as antibiotic agent

### 1.3. Details of the supplier of the safety data sheet

Hospira, A Pfizer Company  
275 North Field Drive  
Lake Forest, Illinois 60045  
1-800-879-3477

Pfizer Ireland Pharmaceuticals  
OSG Building  
Ringaskiddy, Co. Cork.  
Ireland  
+353 21 4378701

**E-mail address** pfizer-MSDS@pfizer.com

### 1.4. Emergency telephone number

**Emergency Telephone** Chemtrec 1-800-424-9300 International Chemtrec (24 hours):+1-703-527-3887

## Section 2: HAZARDS IDENTIFICATION

### 2.1. Classification of the substance or mixture

**Respiratory sensitization** Category 1  
**Skin sensitization** Category 1

#### OSHA Classification

**Hazards not otherwise classified (HNOC)**  
Not applicable

**Hazards classified under paragraph (d)(1)(ii) of 1910.1200**  
Not applicable

### 2.2. Label elements



**Signal word** Danger

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 2 / 11  
Version 2

## Hazard statements

H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled  
H317 - May cause an allergic skin reaction

## Precautionary Statements - EU (§28, 1272/2008)

P272 - Contaminated work clothing should not be allowed out of the workplace  
P261 - Avoid breathing dust/fume/gas/mist/vapors/spray  
P280 - Wear protective gloves/protective clothing/eye protection/face protection  
P304 + P340 - IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing  
P342 + P311 - If experiencing respiratory symptoms: Call a POISON CENTER or doctor/physician  
P333 + P313 - If skin irritation or rash occurs: Get medical advice/attention  
P362 + P364 - Take off contaminated clothing and wash it before reuse  
P501 - Dispose of contents/container in accordance with local, regional, national, and international regulations as applicable  
P302 + P352 - IF ON SKIN: Wash with plenty of soap and water

## 2.3. Other hazards Other hazards

An Occupational Exposure Value has been established for this substance ( see Section 8 ).

## PBT & vPvB

The product does not contain any substance(s) classified as PBT or vPvB.

## Endocrine Disruptor Information

This product does not contain any known or suspected endocrine disruptors.

## Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

## Section 3: COMPOSITION/INFORMATION ON INGREDIENTS

### 3.1 Substances

Hazardous

Chemical name	Weight-%	REACH registration number	EC No (EU Index No)	Classification according to Regulation (EC) No. 1272/2008 [CLP]	Specific concentration limit (SCL)	M-Factor	M-Factor (long-term)
Cefazolin (CAS #: 25953-19-9)	100		247-362-8	Resp. Sens. 1 (H334) Skin Sens. 1 (H317)	Not classified	No data available	No data available

**Full text of H- and EUH-phrases: see section 16**

Acute Toxicity Estimate No information available

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 3 / 11  
Version 2

Chemical name	Oral LD50 mg/kg	Dermal LD50 mg/kg	Inhalation LC50 - 4 hour - dust/mist - mg/L	Inhalation LC50 - 4 hour - vapor - mg/L	Inhalation LC50 - 4 hour - gas - ppm
Cefazolin 25953-19-9	11000	No data available	No data available	No data available	No data available

This product does not contain candidate substances of very high concern at a concentration  $\geq 0.1\%$  (Regulation (EC) No. 1907/2006 (REACH), Article 59).

## Additional information

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.

## Section 4: FIRST AID MEASURES

### 4.1. Description of first aid measures

<b>Inhalation</b>	Remove to fresh air. Seek immediate medical attention/advice.
<b>Eye contact</b>	Rinse thoroughly with plenty of water for at least 15 minutes, lifting lower and upper eyelids. Consult a physician.
<b>Skin contact</b>	Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention. For information on potential delayed effects, see Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
<b>Ingestion</b>	Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

### 4.2. Most important symptoms and effects, both acute and delayed

<b>Most important symptoms and effects</b>	For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
--	--

### 4.3. Indication of any immediate medical attention and special treatment needed

<b>Note to physicians</b>	None.
---------------------------	-------

## Section 5: FIRE-FIGHTING MEASURES

### 5.1. Extinguishing media

<b>Suitable Extinguishing Media</b>	Dry chemical, CO2 or water spray.
-------------------------------------	-----------------------------------

### 5.2. Special hazards arising from the substance or mixture

<b>Specific hazards arising from the chemical</b>	Fine particles (such as dust and mists) may fuel fires/explosions.
<b>Hazardous combustion products</b>	Emits toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, sulfur oxides and other sulfur-containing compounds.
<b>Explosion data</b>	
<b>Sensitivity to mechanical impact</b>	No information available.
<b>Sensitivity to static discharge</b>	No information available.

### 5.3. Advice for firefighters

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 4 / 11  
Version 2

**Special protective equipment and precautions for fire-fighters** Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear. Use personal protection equipment.

## Section 6: ACCIDENTAL RELEASE MEASURES

### 6.1. Personal precautions, protective equipment and emergency procedures

**Personal precautions** Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.  
**For emergency responders** Use personal protection recommended in Section 8.

### 6.2. Environmental precautions

**Environmental precautions** Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

### 6.3. Methods and material for containment and cleaning up

**Methods for containment** Prevent further leakage or spillage if safe to do so.  
**Methods for cleaning up** Contain the source of the spill or leak. Collect spilled material by a method that controls dust generation. Avoid use of a filtered vacuum to clean spills of dry solids. Clean contaminated surface thoroughly.  
**Prevention of secondary hazards** Clean contaminated objects and areas thoroughly observing environmental regulations.

### 6.4. Reference to other sections

**Reference to other sections** See section 8 for more information. See section 13 for more information.

## Section 7: HANDLING AND STORAGE

### 7.1. Precautions for safe handling

**Advice on safe handling** Minimize dust generation and accumulation. Avoid breathing dust/fume/gas/mist/vapors/spray. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.  
**General hygiene considerations** Handle in accordance with good industrial hygiene and safety practice.

### 7.2. Conditions for safe storage, including any incompatibilities

**Storage Conditions** Store as directed by product packaging.

### 7.3. Specific end use(s)

**Specific use(s)** Pharmaceutical drug product.

## Section 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

### 8.1. Control parameters

**Cefazolin**  
Germany TRGS DS  
RS

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 5 / 11  
Version 2

Russia

MAC: 0.3 mg/m<sup>3</sup>

## Pfizer Occupational Exposure Band (OEB) Statement:

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

## 8.2. Exposure controls

### Engineering controls

General room ventilation is adequate unless the process generates dust, mist or fumes. Engineering controls should be used as the primary means to control exposures. Keep airborne contamination levels below the exposure limits listed above in this section.

### Personal protective equipment

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and specific operational processes.

### Eye/face protection

Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the standards in accordance with EN166, ANSI Z87.1 or international equivalent.).

### Hand protection

Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is possible and for bulk processing operations. (Protective gloves must meet the standards in accordance with EN374, ASTM F1001 or international equivalent.).

### Skin and body protection

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations. (Protective clothing must meet the standards in accordance with EN13982, ANSI 103 or international equivalent.).

### Respiratory protection

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international equivalent.).

### Thermal hazards

No information available.

### Environmental exposure controls

No information available.

## Section 9: PHYSICAL AND CHEMICAL PROPERTIES

### 9.1. Information on basic physical and chemical properties

#### Physical state

Powder

#### Color

White

#### Odor

No information available.

#### Odor threshold

No information available

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 6 / 11  
Version 2

<u>Property</u>	<u>Values</u>
Melting point / freezing point	No data available
Boiling point or initial boiling point and boiling range	No data available
Flammability (solid, gas)	No data available
Lower and upper explosion limit/flammability limit	
Lower explosion limit	No data available
Upper explosion limit	No data available
Flash point	No data available
Autoignition temperature	No data available
Decomposition temperature	
SADT (°C)	No data available
pH	No data available
pH (as aqueous solution)	No data available
Kinematic viscosity	No data available
Dynamic viscosity	No data available
Solubility	No data available
Vapor pressure	No data available
Density and/or relative density	No data available
Bulk density	No data available
Liquid Density	No data available
Vapor density	No data available
Particle characteristics	
Particle Size	No information available
Particle Size Distribution	No information available

## 9.2. Other information

Molecular formula	C <sub>14</sub> H <sub>14</sub> N <sub>8</sub> O <sub>4</sub> S <sub>3</sub>
Molecular weight	454.5

### 9.2.1. Information with regard to physical hazard classes

No information available

### 9.2.2. Other safety characteristics

No information available

## **Section 10: STABILITY AND REACTIVITY**

### 10.1. Reactivity

Reactivity No information available.

### 10.2. Chemical stability

Stability Stable under normal conditions.

### Explosion data

Sensitivity to mechanical impact No information available.

Sensitivity to static discharge No information available.

### 10.3. Possibility of hazardous reactions

Possibility of hazardous reactions No information available.

Hazardous polymerization Will not occur.

### 10.4. Conditions to avoid

Conditions to avoid Fine particles (such as dust and mists) may fuel fires/explosions.

### 10.5. Incompatible materials

Incompatible materials As a precautionary measure, keep away from strong oxidizers.

### 10.6. Hazardous decomposition products

Hazardous decomposition products No data available.

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 7 / 11  
Version 2

## Section 11: TOXICOLOGICAL INFORMATION

### 11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

<b>Short term</b>	Inhalation of significant quantities of this substance could result in the health effects described in 'Known clinical effects'. Ingestion of this material can cause effects similar to those seen in clinical use including cholinergic crisis, characterized by severe nausea, vomiting, salivation, sweating, slow heart rate, low blood pressure, muscle weakness, respiratory depression.
<b>Known Clinical Effects:</b>	May cause effects similar to those seen in clinical use including transient diarrhea, nausea and abdominal pain. Individuals sensitive to this material or other materials in its chemical class may develop allergic reactions. Pseudomembranous colitis (manifested by watery diarrhea, urge to defecate, abdominal cramps, low-grade fever, bloody stools, and abdominal pain) may also occur. Concomitant administration of aminoglycosides and cephalosporins has caused nephrotoxicity. Individuals who are sensitive to beta lactam antibiotics, both penicillins and cephalosporins, may experience contact or systemic hypersensitivity and anaphylaxis upon exposure to this drug.
<b>Acute toxicity</b>	Based on available data, the classification criteria are not met.
<b>Serious eye damage/eye irritation</b>	Based on available data, the classification criteria are not met.
<b>Skin corrosion/irritation</b>	Based on available data, the classification criteria are not met.
<b>Respiratory or skin sensitization</b>	Based on available data, the classification criteria are not met.
<b>STOT - single exposure</b>	Based on available data, the classification criteria are not met.
<b>STOT - repeated exposure</b>	Based on available data, the classification criteria are not met.
<b>Reproductive toxicity</b>	Based on available data, the classification criteria are not met.
<b>Germ cell mutagenicity</b>	Based on available data, the classification criteria are not met.
<b>Carcinogenicity</b>	Based on available data, the classification criteria are not met.
<b>Aspiration hazard</b>	Based on available data, the classification criteria are not met.

### Acute Toxicity: (Species, Route, End Point, Dose)

#### Cefazolin

Rat Oral LD50 > 11000 mg/kg

Chemical name	Oral LD50	Dermal LD50	Inhalation LC50
Cefazolin	> 11000 mg/kg ( Rat )	-	-

**Acute Toxicity Comments:** A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

### Irritation / Sensitization: (Study Type, Species, Severity)

#### Cefazolin

Skin Sensitization - GPMT Guinea Pig Negative

**Skin Irritation / Sensitization** Hypersensitivity reactions, including cross reactions (with penicillins) and anaphylaxis, are common among the cephalosporins.

### Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

#### Cefazolin

90 Day(s) Rat Oral 20 mg/kg/day NOEL Gastrointestinal System

3 Month(s) Dog Subcutaneous 250 mg/kg/day NOAEL No effects at maximum dose

6 Month(s) Dog Subcutaneous 125 mg/kg/day NOAEL No effects at maximum dose

### Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Cefazolin

Embryo / Fetal Development Rat Oral 10 mg/kg/day NOEL Maternal toxicity, Not teratogenic

2 Generation Reproductive Toxicity Rat Subcutaneous Dose not specified No effects at maximum dose

Embryo / Fetal Development Rabbit Subcutaneous Dose not specified Not Teratogenic

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 8 / 11  
Version 2

## Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

### Cefazolin

*In Vitro* Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative  
*In Vitro* Micronucleus Mouse Negative  
*In Vitro* Mammalian Cell Mutagenicity Mouse Lymphoma Negative

**Carcinogenicity** Not listed as a carcinogen by IARC, NTP or US OSHA.

## 11.2. Information on other hazards

### 11.2.1. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 11.2.2. Other information

**Other adverse effects** No information available.

## Section 12: ECOLOGICAL INFORMATION

**Environmental Overview:** The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

### 12.1. Toxicity

### 12.2. Persistence and degradability

**Persistence and degradability** No information available.

### 12.3. Bioaccumulative potential

**Bioaccumulation** No information available.

### 12.4. Mobility in soil

**Mobility in soil** No information available.

### 12.5. Results of PBT and vPvB assessment

**PBT and vPvB assessment** Based on available data, the classification criteria are not met.

### 12.6. Endocrine disrupting properties

**Endocrine disrupting properties** Based on available data, the classification criteria are not met.

### 12.7. Other adverse effects

**Other adverse effects** No information available.

**PMT or vPvM properties** Based on available data, the classification criteria are not met.



# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 9 / 11  
Version 2

## Section 13: DISPOSAL CONSIDERATIONS

### 13.1. Waste treatment methods

#### Waste from residues/unused products

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural wastewater and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

## Section 14: TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

UN number:	Not applicable
UN proper shipping name:	Not applicable
Transport hazard class(es):	Not applicable
Packing group:	Not applicable
Environmental Hazard(s):	Not applicable

## Section 15: REGULATORY INFORMATION

### 15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

Cefazolin

CERCLA/SARA Section 313 de minimus %	Not Listed
California Proposition 65	Not Listed
EINECS	247-362-8
Standard for Uniform Scheduling of Medicines and Poisons (SUSMP)	Schedule 4

#### National regulations

##### Germany

Chemical Prohibition Ordinance (ChemVerbotsV)  
Not applicable

TRGS 905 Not applicable

##### Switzerland

Ordinance on the Incentive Tax on Volatile Organic Compounds (OVOC) SR 814.018	Not applicable
Storage of Hazardous Material	Not applicable
WPO (GSchV) SR 814.201; WPA (GSchG) SR 814.20	Not applicable

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 10 / 11  
Version 2

## Major Accidents Ordinance SR 814.012

Not applicable

## European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

## Authorizations and/or restrictions on use:

This product does not contain substances subject to authorization (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

## Persistent Organic Pollutants

Not applicable

## Ozone-depleting substances (ODS) Regulation (EU) 2024/590

Not applicable.

## Explosives Precursors Marketing and Use (2019/1148)

Not applicable

### Legend:

**TSCA** - United States Toxic Substances Control Act Section 8(b) Inventory

**DSL/NDL** - Canadian Domestic Substances List/Non-Domestic Substances List

**EINECS/ELINCS** - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

**ENCS** - Japan Existing and New Chemical Substances

**IECSC** - China Inventory of Existing Chemical Substances

**KECL** - Korean Existing Chemicals Inventory

**PICCS** - Philippines Inventory of Chemicals and Chemical Substances

**AICS** - Australian Inventory of Chemical Substances

**NZIoC** - New Zealand Inventory of Chemicals

**TCSI** - Taiwan Chemical Substance Inventory

## 15.2. Chemical safety assessment

### Chemical Safety Report

No information available

## Section 16: OTHER INFORMATION

### Key or legend to abbreviations and acronyms used in the safety data sheet

### Full text of any hazard and/or precautionary statements referred to under Sections 2-15

H334 - May cause allergy or asthma symptoms or breathing difficulties if inhaled H317 - May cause an allergic skin reaction

### Data Sources:

Publicly available toxicity information.

### Reason for revision

Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 12 - Ecological Information.

### Revision date

17-Jun-2025

# SAFETY DATA SHEET

Product Name Cefazolin for Injection (Hospira, Inc.)  
Revision date 17-Jun-2025

Page 11 / 11  
Version 2

---

## Prepared By

Pfizer Global Environment, Health, and Safety

**Pfizer Inc believes that the information contained in this Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.**